TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet criteria for primary alcohol dependence including loss of control of drinking~* No more than one previous inpatient medical detoxification~* Consumes on average 5 standard drinks for men and 4 standard drinks for women~* Able to maintain sobriety for 4 days (with or without detox medications).~* Able to read and understand questionnaires and Informed Consent~* Lives within 50 miles of the study site~Exclusion Criteria:~* Currently meets DSM-IV criteria for any other psychoactive substance dependency disorder except nicotine dependence~* Ever abused opiates~* Any psychoactive substance abuse, except marijuana and nicotine within the last 30 days as evidenced by subject report, collateral report, or urine drug screen.~* Meets DSM-IV criteria for current Axis I disorder of major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, dissociative disorder or eating disorder, schizophrenia, or any other psychotic disorder or organic mental disorder.~* Has current suicidal or homicidal ideation~* Need for maintenance or acute treatment with any psychoactive medication including antiseizure medications.~* Current use of disulfiram.~* Clinically significant medical problems, such as cardiovascular, renal, GI or endocrine problem that would impair participation or limit medication ingestion.~* Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days of abstinence.~* Sexually active females of child bearing potential who are pregnant (by urine HCG), nursing or who are not using a reliable form of birth control.~* Has current charges pending for a violent crime (not including DUI related offenses).~* Does not have a stable living situation and a reliable source of collateral reporting.~* Has taken an opiate antagonist drug in the last month.~* Has taken gabapentin in the last month or has experienced adverse effects from it at any time in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Naltrexone plus placebo
- 2 (Type: ACTIVE_COMPARATOR): naltrexone + gabapentin
- 3 (Type: SHAM_COMPARATOR): Placebo plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients signed the written informed consent~* Women aged 18-70.~* The pathologic diagnosis of recurrent metastatic triple negative breast cancer ［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.~* At least one measuring lesion that conforms to RECIST v1.1 standard.~* The number of chemotherapy lines in the metastatic phase was \<3 line.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.~* Have a life expectancy of at least 12 weeks.~* Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment.~* The patients can swallow pills.~* The results of patients' blood tests are as follows: • Hb≥90g/L; • Plt≥90E+9/L; • Neutrophils≥1.5E+9/L; • ALT and AST ≤ triple of normal upper limit; • TBIL ≤ 1.5 times of normal upper limit; • Creatinine ≤ 1.5 times of normal upper limit.~Exclusion Criteria:~* The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.~* Subjects with severe allergic reactions to other monoclonal antibodies.~* The subjects had a central nervous system metastases with clinical symptoms.~* History of hypertension and antihypertensive medications are not well controlled.~* A heart condition or disease that is not well controlled.~* Subjects had active infections or recent treatment with a systemic immunostimulatory agent (received within the previous 4 weeks).~* Other clinical trials of drugs were used in the first four weeks of the first medication.~* Subjects with treatment history of anti-angiogenesis drugs or check-point inhibitors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210 +Apatinib daily dosing (Type: EXPERIMENTAL): SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
- SHR-1210+Apatinib intermittent dosing (Type: EXPERIMENTAL): SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Connected Healthcare for Individuals Living at Home With Chronic Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. English speakers~2. age 50 and over~3. diagnosed with one or more chronic condition(s) and~4. currently taking ﬁve or more prescribed oral medications.~5. City of Calgary resident~Exclusion Criteria:~* Patients with moderate to severe cognitive impairment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Intervention group included medication management with Spencer.
- Control Group (Type: NO_INTERVENTION): The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal Patients~* Patients with histologically confirmed endometrial hyperplasia without atypia~Exclusion Criteria:~* Endometrial hyperplasia with atypia~* Endometrial Carcinoma~* Suspected pathology on Physical/Ultrasonographic Examination e.g. fibroids, adnexal abnormality

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal Micronized Progesterone (Type: EXPERIMENTAL): Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
- LNG-IUS (Type: ACTIVE_COMPARATOR): Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HSAN1 patients with prominent sensory loss with foot ulcers or shooting pains and con-firmed mutations in SPTLC1.~* Males and females of 18 years or older~* All patients will be able to provide informed consent and comply with oral dietary supple-mentation and study activities. Compliance with supplementation will be monitored through measurement of DSB levels.~* Subjects must not have taken L-serine for at least 30 days prior to randomization (L-serine-naïve subjects are permitted in the study).~* Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study.~Exclusion Criteria:~* Any cause of neuropathy other than HSAN1 (such as diabetes or drug-induced neuropathy), medical history of kidney stones, or history of poliomyelitis or radiotherapy.~* Pregnant women, breastfeeding, or not using adequate contraception; for women included, an accepted method of contraception will be used throughout the study.~* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.~* Patients on blood-thinners such as warfarin (Coumadin) or heparin will not be biopsied until they have held the medication for 5 days. Following the biopsy they will resume the maintenance dose of their medication.~* Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 10 days prior to study entry.~* The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to PI judgment, or a history of active substance abuse within the prior year.~* Subjects who are non-ambulatory.~* Subjects with uncontrolled diabetes.~* Patients who are unable or unwilling to give consent will not be enrolled in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo arm
- L-serine (Type: ACTIVE_COMPARATOR): amino acid supplementation with L-serine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥20 and ≤60 years of age~* In good health as determined by medical history, physical examination, and clinical judgment of the investigator~* Willing and able to comply with all required study visits and follow-up required by this protocol~* Must provide written informed consent~Exclusion Criteria:~* Known or potential exposure to avian influenza virus or any H5N1 HA antigen vaccine~* Had any influenza vaccine within 6 months~* Administered with any vaccine within 30 days~* A history of hypersensitivity to vaccines or inflammatory or degenerative neurological disease~* Receiving chronic administration of immunosuppressants or other immune-modifying drugs within 6 months~* Known HIV, hepatitis B (HBsAg) or hepatitis C seropositivity~* Any medical illness including clinically significant acute pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests~* Receiving immunoglobulins and/or any blood products within the three months~* Acute disease at the time of enrolment~* Psychiatric, addictive, or any disorder, which may compromise the ability to give a truly informed consent for participation of this study or adequate compliance~* Breast feeding or pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Low Dosage AT-301 (Type: EXPERIMENTAL): 7.5 µg hemagglutinin (HA)
- Middle Dosage AT-301 (Type: EXPERIMENTAL): 15 µg hemagglutinin (HA)
- High Dosage AT-301 (Type: EXPERIMENTAL): 30 µg hemagglutinin (HA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Plus Metformin in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese patients with PCOS~Exclusion Criteria:~* Other causes of hyperandrogenism and~* Use of drugs including:~  * oral contraceptive~ * anti-hypertensive agents~ * anti-diabetic drugs~ * agents for weight loss

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): 850 mg/day twice a day
- Metformin plus spironolactone (Type: ACTIVE_COMPARATOR): Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Female or male patients ≥18 years with WHO performance status ≤ 1~* HER-2 overexpressing metastatic breast cancer cells confirmed by histology~* Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy~* Patients neurologically stable with adequate bone marrow, liver and renal function~Exclusion criteria:~* Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study treatment start~* Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these ≤ 4 weeks prior to study treatment start or patients who have received lapatinib ≤ 2 weeks prior to study treatment start~* Patients who have previously received vinorelbine or mTOR inhibitors~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 Daily Schedule (Type: EXPERIMENTAL): 5mg or 10mg
- RAD001 Weekly Schedule (Type: EXPERIMENTAL): 30mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatient or outpatients, ages 18-65~Exclusion Criteria:~* Participation in a clinical trial of another drug including olanzapine or aripiprazole within 30 days prior to study entry (visit 1).~* Treatment with clozapine within the past 12 months.~* Have known uncorrected narrow-angle glaucoma.~* Have a diagnosis of Parkinson's disease, dementia or related disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* Ability to exercise~* Ability to computer mouse to provide ratings~* \> 10 pack-years smoking~* Baseline dyspnea index \< 9~Exclusion Criteria:~* Clinically significant comorbidities

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A: naloxone; B: normal saline (Type: PLACEBO_COMPARATOR): Arm A: IV naloxone Arm B: IV normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Anti-Caries Varnish

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject's parent or legal guardian must provide signed and dated informed consent (parent permission form).~2. The subject's parent or legal guardian of the subject must be willing and able to comply with study requirements.~3. The subject is a 10-20 months at the time of enrollment.~4. The subject must be in good general health as evidenced by parent report.~5. The subject will have at least 1 erupted tooth that is either sound or has only a d1 (white spots) lesion.~Exclusion Criteria:~1. Previous treatment with fluoride varnish~2. Known allergy to iodine~3. Diagnosis of thyroid disease~4. Chronic, prophylactic use of antibiotics~5. Treatment with another investigational drug or intervention within 30 days preceding the Baseline Visit.~6. Visible cavities (d2-4)~7. Presence of intraoral pathology that would make assessment of post treatment soft tissue ulcerations or inflammation impossible (child could be enrolled if problem is treated and lesions cleared)~8. Parent anticipates the child will move from Pohnpei during the next 2 years.

- Gender: ALL
- Minimum Age: 10 Months
- Maximum Age: 20 Months
- Healthy Volunteers: t

Study Arms:
- Test Varnish (Type: EXPERIMENTAL): Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
- Control Varnish (Type: ACTIVE_COMPARATOR): Control Varnish. 5% (w/v) Sodium Fluoride .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Mentally and physically healthy~* BMI between 18 and 32 kg/m\^2~* Two pre-treatment semen samples \> 20 million/ml with normal morphology and motility~Exclusion Criteria:~* History or presence of psychiatric disease, liver disease, renal disease, diabetes, cardiovascular disease, any malignancy, prostatic disease, or genitourinary infection~* PSA \> 2.5 ng/ml~* Use of drugs known to interfere with pharmacokinetics of steroids~* Use of lipid-lowering drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): etonogestrel with testosterone undecanoate
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy~* Discontinuation of all drugs used to treat underlying MF disease at least 14 days prior to baseline visit~* INR \<= 1.5 or PTT value \< 1.5 x upper limit of normal (ULN) at study entry~* Hemoglobin level at least 6.5 g/dL at Screening visit~* Willingness to be transfused to treat low hemoglobin levels~Exclusion Criteria:~* Females who are pregnant, unable to comply with birth control use to avoid becoming pregnant or breastfeeding~* Males who cannot comply with birth control use to avoid fathering a child~* Platelet count \< 50 x10\^9/L or absolute neutrophil count (ANC) \< 1 x10\^9/L at the Screening visit~* Inadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be \> 1.5 x upper limit of normal at study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib 5 mg (Type: EXPERIMENTAL): Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete